In vitro phosphorylation of BRCA2 by the checkpoint kinase CHEK2 by Kim, S et al.
Short Communication
In vitro phosphorylation of BRCA2 by the checkpoint kinase
CHEK2
S Kim
1, G Mohapatra
2 and DA Haber*,1
1Massachusetts General Hospital Cancer Center, Harvard Medical School, Massachusetts General Hospital, Charlestown, MA 02129, USA;
2Department of Pathology, Harvard Medical School, Massachusetts General Hospital, Charlestown, MA 02129, USA
Germline mutations in both BRCA2 and CHEK2 are associated with an increased risk for male breast cancer. To search for potential
interactions between the products of these breast cancer susceptibility genes, we undertook systematic mapping of BRCA2 for
potential phosphorylation sites by CHEK2. In vitro kinase assays and mass spectrometric analysis identified a 50 amino-acid fragment
within the N-terminus of BRCA2 potentially targeted by CHEK2, containing two major phosphopeptides. Inducible overexpression of
this peptide, but not a derivative with mutated phosphorylation sites, leads to increased chromosome fragmentation and suppression
of cellular proliferation. These results suggest a link between CHEK2 and BRCA2 pathways, which may contribute to the spectrum of
cancers associated with germline CHEK2 mutations.
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CHEK2 (also known as CHK2) encodes an ATM-dependent serine-
threonine kinase that modulates a conserved DNA damage
checkpoint pathway (Ahn et al, 2004). Although its orthologs
Rad53 (Saccharomyces cerevisiae) and Cds1 (Schizosaccharomyces
pombe) are integral components of the G2/M DNA damage
checkpoint (Sanchez et al, 1996; Rhind et al, 2000), mammalian
CHEK2 has been reported to mediate phosphorylation of a number
of targets, implicated in multiple aspects of cell cycle progression
and DNA damage repair (Zhou and Elledge, 2000; Bartek et al,
2001). By analogy with its yeast orthologs, CHEK2 was first shown
to phosphorylate Cdc25C on Ser216, leading to its cytoplasmic
sequestration by 14-3-3 proteins, and preventing the depho-
sphorylation and activation of Cyclin B/Cdc2, thus mediating a G2
arrest (Peng et al, 1997; Sanchez et al, 1997; Matsuoka et al, 1998).
Subsequently, CHEK2 was shown to have additional targets,
including Cdc25A (Ser123) leading to its destabilisation and
activating the S-phase checkpoint (Mailand et al, 2000; Falck et al,
2001); p53 (Ser20), linked to its activation following ionising
radiation (IR) and modulating a G1/S arrest (Chehab et al, 2000;
Hirao et al, 2000; Shieh et al, 2000); and BRCA1 (Ser988),
implicated in its altered subnuclear localisation (Lee et al, 2000).
Although these pathways have been studied primarily in cancer
cell lines, a number of mouse models of CHEK2 inactivation have
provided some insight into the physiologically relevant pathways
(Hirao et al, 2002; Takai et al, 2002). These have demonstrated a
mild attenuation of p53 function, with modest tumorigenesis, but
significant synergistic effects following inactivation of both CHEK2
and Brca1 (McPherson et al, 2004).
In humans, CHEK2 inactivation is thought to mediate a
moderately increased risk for breast and possibly prostate
cancers (Allinen et al, 2001; Meijers-Heijboer et al, 2002;
Seppala et al, 2003; Cybulski et al, 2004). Germline mutations
were initially identified in families with Li Fraumeni-like
multicancer syndromes lacking the characteristic mutation in
p53 (Bell et al, 1999). Subsequent population-based studies have
shown that a recurrent loss of function CHEK2 mutant,
CHEK21100delC is present in approximately 1% of the
population and in 5% of familial breast cancer families lacking a
BRCA1 or BRCA2 mutation (Meijers-Heijboer et al, 2002;
Fernandez-Novoa et al, 2004). The fact that BRCA1/2 kindreds
displayed no increase in CHEK21100delC mutation frequency was
taken as evidence that CHEK2 may function in a similar pathway,
thus obviating the need for redundant mutations. Most signifi-
cantly, the frequency of CHEK21100delC in breast cancer
families with a case of male breast cancer was as high as 13%
(Meijers-Heijboer et al, 2002). Given the relatively unique nature
of the link between BRCA2 mutations and male breast cancer, we
therefore sought evidence of a functional interaction between
BRCA2 and CHEK2.
MATERIALS AND METHODS
Generation of constructs and conditionally expressing cell
lines
Overlapping serial fragments of BRCA2, with the exception of
the extreme C terminus, which could not be expressed in vitro,
were constructed by PCR and introduced into pGEX2T to
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sexpress GST-fusion proteins. Proteins were expressed in BL21
cells, followed by Glutathione Sepharose 4B bead purification,
and dialysis (20mM HEPES, pH 7.4, 20% glycerol, and 0.5mM
PMSF) of purified proteins. The B2P fragment, containing either
wild-type sequence of 50 amino-acids spanning the CHEK2 targets,
or a mutated version was fused to a Flag at the N-terminus
and SV40 NLS at the C-terminus and cloned into the tetra-
cycline-regulated vector pUHD10.3. Inducible expression of a
wild-type B2P (WT), a mutant version with all four serine/
threonine to alanine/valine, or a previously described BRC
repeat fragment, BRC4 (Chen et al, 1999) was achieved by
co-transfecting a U2OS founder cell line with the corresponding
pUHD10.3 construct, along with a plasmid encoding hygromycin
resistance. Hygromycin-resistant clones were selected for compar-
able levels of inducible B2P expression by western blot analysis,
and at least two independent clones were selected for each
construct for functional assays.
In vitro kinase assays
In vitro kinase assays were performed using either cellular CHEK2
derived from U2OS cells with inducible expression, immuno-
precipitated using anti-Flag antibody, 1h after g-irradiation
(10Gy), or purified bacterially expressed GST-CHEK2 proteins.
Various fragments of GST-BRCA2 (B2P-WT or -mutants) were
used as substrates in a 30-min incubation using 20mM HEPES (pH
7.4), 10mM MgCl2,1 0 m M MnCl2,4 0 mM ATP, and 15mCi
[g-
32P]ATP at 301C.
Cell growth assays and chromosome spreading and GTG
banding
Equal numbers of cells (5 10
4) with inducible expression of
B2P-WT, B2P-M9, or BRC4 were plated onto six-well plates in the
presence of tetracycline (1mgml
 1). Tetracycline was withdrawn
after 24h and viable cells were counted at the indicated times. For
chromosome analysis, equal numbers of cells (5 10
5) were plated,
followed by inducible expression of the appropriate constructs and
treatment of cells with colchicine (10mgml
 1) for 20h. Cells were
then treated with trypsin and Giemsa for GTG banding as
described (Thalhammer et al, 2001). Individual metaphases were
photographed and scored blindly for abnormal structures and
broken chromosomes.
Statistical methods
The comparison of mean fragment/metaphase between two groups
was performed by two-sided Student’s t-test. We performed two
comparisons (i.e., comparisons of WT vs BRC4, and M9 vs BRC4),
and the Bonferroni’s correction was applied to the significance
level of each comparison. A P-value o0.025 was considered as a
statistically significant result.
RESULTS AND DISCUSSION
To search for potential CHEK2 phosphorylation sites within
BRCA2, we first generated a series of overlapping glutathione
S-transferase (GST)-fusion proteins spanning the BRCA2
coding sequence, with the exception of the extreme C terminus,
which could not be expressed in vitro (Figure 1). Purified
GST-BRCA2 fragments were incubated with either bacterially
expressed GST-CHEK2 or with immunoprecipitates of CHEK2
derived from X-irradiated (10Gy) U2OS cells expressing a
tetracycline-regulated Flag-tagged construct. A single N-terminal
fragment of BRCA2 (amino acids 1–450) showed reproducible
in vitro phosphorylation by both GST-CHEK2 and immunopreci-
pitated CHEK2 proteins, comparable in intensity to the
988Serine-
containing BRCA1 fragment previously identified as a CHEK2
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Figure 1 Phosphorylation of the N-terminal fragment of BRCA2 (B2P) by CHEK2 in vitro. Schematic representation of BRCA2 in seven overlapping GST-
fusion proteins, designated 1–7, and used for in vitro kinase assays. Fragment 1 was further subdivided into the three overlapping GST-fusion proteins, 1.1,
1.2, and 1.3, and the fragment 1.3 region was divided again into fragments 1.3.1, 1.3.2, 1.3.3, and 1.3.4. The final peptide containing specific CHEK2
phosphorylation sites was designated B2P: it has 50 amino acids with four putative substrate sites (shown in red), identified by mass-spectrometric
analysis. The mass-spectrometric analysis was performed by using fragments of BRCA2 expressed from bacteria as GST-fusion proteins with either
bacterially expressed GST-CHEK2 or immunoprecipitated Flag-CHEK2 from IR-treated tissue culture cells. The right panel shows the in vitro CHEK2
phosphorylation assay for each step of analysis with BRCA2 fragments. GST-BRCA1 fragment containing S988 and GST alone were used as positive and
negative controls.
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starget (Figure 1, data not shown). Through a series of further
subcloning experiments, the putative CHEK2 target sequence was
narrowed to 50 amino-acid residues (aa 400–450), referred to as
B2P. (Figures 1 and 2A). Mass-spectrometric analysis of B2P,
following coincubation with either GST-CHEK2 or immuno-
precipitated CHEK2 from irradiated cells, identified four
phosphorylated residues:
417Serine,
418Serine,
442Serine, and
441Threonine (Figures 1 and 2B, C) and
418Serine is well conserved
in most mammals (Supplementary data).
To test the contribution of each Serine and Threonine residues
to CHEK2-mediated phosphorylation, we undertook site-directed
mutagenesis of B2P, substituting unphosphorylatable residues
(Serine to Alanine, and Threonine into Valine), either alone or in
combination (mutant peptides M1-9, Figure 2B). Fragments
containing single, double, triple, or quadruple mutations were used
as substrates for in vitro GST-CHEK2-mediated phosphorylation.
Of peptides with a single substitution, only M4 (targeting
442Ser)
showed a reduction in CHEK2-dependent phosphorylation using
either GST-CHEK2 or immunoprecipitated CHEK2 from irradi-
ated cells (Figure 2B and C). Peptides with multiple substitu-
tions including S442A (M6, M7, M8, M9) also showed reduced
CHEK2 phosphorylation, whereas a multisubstituted peptide
with an unaltered
442Ser (M5) had preserved CHEK2 phosphory-
lation (Figure 2B). Taken together, these studies point to
442Ser
as the potentially major CHEK2 substrate in BRCA2, with
additional minor targets including
417Serine,
418Serine, and
441Threonine.
Robust and specific assays of BRCA2 function are limited, but
brca2-deficient cells are known to have a striking increase in
chromosomal defects (Patel et al, 1998; Venkitaraman, 2002). To
define a potential functional assay for BRCA2 phosphorylation at
residues localised to the B2P fragment, we generated cell lines with
tetracycline-regulated inducible expression of this peptide or a
mutant peptide with all four substituted CHEK2-target residues.
The osteosarcoma cell line U2OS was selected for these experi-
ments, given its near diploid and stable karyotype, wild-type
endogenous p53, and the availability of tightly regulated tetra-
cycline-regulatable founder cell lines. Cell lines were generated,
with inducible expression of wild-type or mutated (M9) B2P
peptide, linked to a nuclear localisation signal (NLS) and a Flag
epitope. In multiple cell lines, tightly regulated expression was
achievable with both constructs, although the mutant was
consistently induced to higher levels than the wild-type peptide
(Figure 3A). As control, we also generated cells with inducible
expression of BRC4 (Figure 3A), a BRCT-containing fragment of
BRCA2, which has been reported to disrupt the RAD51-dependent
function of BRCA2 (Chen et al, 1999). Inducible expression of
wild-type B2P, but not the M9 mutant, led to a reduction in cell
proliferation, similar to that observed following induction of BRC4
(Figure 3B). As the inactivation of BRCA2 is known to result in
spontaneous disruption of chromosome structure (Chen et al,
1999), we examined chromosome spreads of U2OS cells with
inducible expression of B2P using GTG banding. A reproducible
increase in chromosome fragments per metaphase was observed
48h following induction of wild-type B2P, but not the M9 mutant
(Figure 3C and D). The effect of B2P peptide expression was
comparable to that of BRC4 (Figure 3C and D). There was no
statistically significant difference in mean fragment/metaphase
between B2P-WT and BRC4. The mean fragment/metaphase levels
between B2P-M9 and BRC4 were significantly different
(Po0.0001). Thus, ectopic overexpression of the BRCA2 fragment
containing intact CHEK2 phosphorylation sites may disrupt
endogenous gene product function, leading to chromosomal
instability.
CONCLUDING REMARKS
Our studies suggest a potential functional link between the CHEK2
kinase and the BRCA2 tumour suppressor, which may explain
in part the increased incidence of male breast cancer observed
in families with germline mutations in both of these genes (Couch
et al, 1996; Haraldsson et al, 1998; Meijers-Heijboer et al, 2002).
While factors affecting BRCA2 protein function are poorly
understood, two other kinases have recently been implicated
in its regulation (Lin et al, 2003; Lee et al, 2004; Esashi et al, 2005).
CDK-dependent phosphorylation of the C-terminal BRCT domain
(Ser 3291) has been shown to modulate the BRCA2–RAD51
interaction in a cell cycle-dependent manner. This interaction
was disrupted by ectopic expression of BRCA2-derived peptides
containing the phosphorylation target site (Esashi et al, 2005).
In addition, polo-like kinase 1 (PLK1) has been shown to
phosphorylate the N terminus of BRCA2, modulating its dis-
sociation from a transcriptional co-activator protein, P/CAF,
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Figure 2 BRCA2 residues targeted by CHEK2 phosphorylation. (A) The
four residues containing putative phosphorylation sites in the BRCA2
fragment B2P were mutagenised individually or in combination as shown.
(B) Phosphorylation of wild type (WT) or mutant forms of B2P fragments
by CHEK2. GST-fusion proteins were incubated with bacterially expressed
GST-CHEK2 proteins in the presence of [g-
32P]ATP. This in vitro kinase
assay was repeated three times with similar results. (C) Phosphorylation of
B2P by immunoprecipitated CHEK2, following in vivo activation by ionising
radiation. Flag-tagged CHEK2 protein was induced for 24h in U2OS cells
with tetracycline-regulated expression, and lysates were collected 1h
following treatment with 10Gy and immunoprecipitated using either anti-
Flag or nonspecific (control) antibodies. Wild-type (WT) or mutant
(M4, M9) GST-fusion B2P fragments were incubated with the immuno-
precipitates in the presence of
32P. Phosphorylation of wild-type, but not
mutant, GST-BRCA2 fragments is evident in CHEK2 immunoprecipitates.
Flag-CHEK2 itself shows autophosphorylation as well. Total lysates (10mg)
were immunoblotted to show comparable expression of Flag-CHEK2
(western blot control).
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swith intrinsic histone acetyltransferase activity (Lin et al, 2003; Lee
et al, 2004). The effect of CHEK2 on BRCA2 remains to be
confirmed in vivo, as does its effect on potential functional
properties of BRCA2. Nonetheless, the potential modulation
by CHEK2 of both BRCA1 and BRCA2 would point to
an important function for this checkpoint kinase in the
DNA damage repair pathways implicated in the development of
breast cancer.
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